… Erlotinib (Tarceva™; OSI Pharmaceuticals, Genentech and Roche), a quinazoline derivative
… kinases that has been studied in clinical trials. In a Phase I study, mild diarrhoea and mild …

… with advanced non–small cell lung cancer (NSCLC). We evaluated erlotinib in the frontline
… The promising efficacy of erlotinib monotherapy in this study suggests that such therapy is a …

… The BR.21 study was a phase 3 trial of erlotinib involving patients who had had … small-cell
lung cancer. Patients were randomly assigned in a 2:1 ratio to receive 150 mg of erlotinib daily …

… Symptom improvement in lung cancer patients treated with erlotinib: quality of life
analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. …

… studies established a fixed daily oral dose of 150 mg as the recommended dose for
Phase II studies… with EGFR-positive non-small cell lung cancer after failure of platinum-containing …

… study examined the efficacy and safety of erlotinib combined with cisplatin and gemcitabine
for first-line treatment of advanced NSCLC. Overall, the erlotinib … 43 weeks for erlotinib plus …

… The epidermal growth factor receptor (EGFR) mutation rate is low in lung SCC. The aim of
this study was to evaluate the status of erlotinib treatment and EGFR mutation in lung SCC …

Background We conducted a randomized, placebo-controlled, double-blind trial to determine
whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non–…

… contribute to the benefit observed with sequential erlotinib in this study. Indeed, two patients
with EGFR mutations obtained a substantial benefit with sequential erlotinib (PFS, 56 to 82+ …

… Similarly, results from the phase III BR.21 study indicated that erlotinib conferred a clinical
… erlotinib therapy. There were no unexpected safety findings relating to erlotinib in this study. …